title: PD168077, a D(4) receptor agonist, reverses object recognition deficits in rats: potential role for D(4) receptor mechanisms in improving cognitive dysfunction in schizophrenia.
abstract: This study investigated the effects of the dopamine D(4) receptor agonist, PD168077, on recognition memory using a novel object recognition task, which detects disruption and improvement of recognition memory in rats by measuring their ability to discriminate between familiar and novel objects. When acquisition and test were 6 h apart (experiment 1), control rats failed to discriminate between familiar and novel objects at test. Rats given low doses of PD168077 (0.3; 1.0 mg/kg) also failed to discriminate between the objects, while rats given higher doses (3.0; 10.0 mg/kg) explored the novel object more than the familiar object, indicating retained memory of the familiar object. Thus, at higher doses, PD168077 improved recognition memory in rats. Experiment 2 tested whether PD168077 would attenuate deficits in novel object recognition induced by sub-chronic phencyclidine. Testing was 1 min after acquisition, such that vehicle pre-treated rats differentiated between the novel and familiar objects: however, sub-chronic phencyclidine-treated rats failed to discriminate between the two, indicating disruption of recognition memory. PD168077 (10 mg/kg) restored the ability of phencyclidine-treated rats to differentiate between the novel and familiar objects, indicating improved recognition memory. The results suggest that D(4) receptor activation can improve cognitive dysfunction in an animal model relevant to schizophrenia.
authors.affiliation: School of Psychology, University of Leicester, Leicester, UK.
authors.forename: Pooja
authors.initials: P
authors.lastname: Sood
authors.forename: Nagi F
authors.initials: NF
authors.lastname: Idris
authors.forename: Susan
authors.initials: S
authors.lastname: Cole
authors.forename: Ben
authors.initials: B
authors.lastname: Grayson
authors.forename: Joanna C
authors.initials: JC
authors.lastname: Neill
authors.forename: Andrew M J
authors.initials: AM
authors.lastname: Young
mesh_terms: D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D003072:Cognition Disorders / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D004192:Discrimination, Psychological / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D010622:Phencyclidine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D050638:Receptors, Dopamine D4 / Q000819:agonists*; D021641:Recognition, Psychology / Q000187:drug effects*; D012565:Schizophrenic Psychology
chemical_list: D001549:Benzamides; C477501:N-((4-(2-cyanophenyl)-1-piperazinyl)methyl)-3-methylbenzamide; D010879:Piperazines; D050638:Receptors, Dopamine D4; D010622:Phencyclidine